(Reuters) - H. Lundbeck * Otsuka and lundbeck submit new drug application (NDA) to the United States Food and Drug Administration (FDA) for brexpiprazole for the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression * The NDA is supported by seven completed clinical Phase 2 or 3 studies in proposed indications * Clinical development program included more than 6,500 individuals, including more than 5,300 who received brexpiprazole Source text for Eikon
Oh boy, Abilify’s successor. Not much new novel treatment here. Not predicting great things for this med.
If this drug is anything close to how Abilify works - I will be steering far away from it - if it is different from how Abilify works, I just may give it a shot. I do not think that partial dopamine agonists work so well for me. Being on Abilify (for me) did not work out so well